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Current research on antiretroviral therapy is mainly focused in the development of
new formulations or combinations of drugs belonging to already known targets.
However, HIV-1 infection is not cured by current therapy and thus, new approaches
are needed. Bevirimat was developed by chemical modification of betulinic acid, a
lupane-type pentacyclic triterpenoid (LPT), as a first-in-class HIV-1 maturation inhibitor.
However, in clinical trials, bevirimat showed less activity than expected because of
the presence of a natural mutation in Gag protein that conferred resistance to a high
proportion of HIV-1 strains. In this work, three HIV-1 inhibitors selected from a set of
previously screened LPTs were investigated for their targets in the HIV-1 replication
cycle, including their maturation inhibitor effect. LPTs were found to inhibit HIV-1 infection
acting as promiscuous compounds with several targets in the HIV-1 replication cycle.
LPT12 inhibited HIV-1 infection mainly through reverse transcription, integration, viral
transcription, viral proteins (Gag) production and maturation inhibition. LPT38 did it
through integration, viral transcription or Gag production inhibition and finally, LPT42
inhibited reverse transcription, viral transcription or Gag production. The three LPTs
inhibited HIV-1 infection of human primary lymphocytes and infections with protease
inhibitors and bevirimat resistant HIV-1 variants with similar values of IC50. Therefore,
we show that the LPTs tested inhibited HIV-1 infection through acting on different targets
depending on their chemical structure and the activities of the different LPTs vary with
slight structural alterations. For example, of the three LPTs under study, we found that
only LPT12 inhibited infectivity of newly-formed viral particles, suggesting a direct action
on the maturation process. Thus, the multi-target behavior gives a potential advantage
to these compounds since HIV-1 resistance can be overcome by modulating more than
one target.
Keywords: HIV-1, antiretrovirals, maturation, triterpenoids, lupanes, promiscuous compounds, multi-target
compounds
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INTRODUCTION
Drug discovery has been classically focused on the development
of highly selective single-target drugs in order to minimize
undesired side effects. However, the ever-increasing rate of
failure during late-stage clinical development is changing the
drug discovery landscape by considering new strategies (Senger
et al., 2016). Compound promiscuity (Hu and Bajorath, 2013)
which provides polypharmacology drug behavior is a main
concern in drug discovery (Morphy and Rankovic, 2005) and
a number of computational approaches (Sturm et al., 2012;
Abdolmalek et al., 2017) and NMR (LaPlante et al., 2013)
strategies have been introduced to understand the molecular
basis for drug promiscuity. Furthermore, multi-target drugs
have become a hotspot in new drug research and development,
showing themselves to be effective in reducing the likelihood
of drug resistance, diminishing problems of dosing complexity,
drug-drug interactions and toxicities, as well as improving
patient compliance. Multi-target drugs offer an advantage in
the treatment of certain complex diseases by modulating more
than one target, and this approach becomes especially relevant
in complex (multi-factorial) diseases such as cancer and AIDS
(Zhan and Liu, 2009).
Lupane-type pentacyclic triterpenoids (LPTs) have been
extensively studied as anti-HIV agents, providing a versatile
structural platform for the discovery of new biologically active
compounds, and thus, the molecular structure of the LPTs
could be considered as a privileged structure since they can be
recognized by distinct receptors, leading to a broad range of
pharmacological activities (Vasilevsky et al., 2011). In particular,
LPTs have been extensively studied as anti-HIV agents, providing
a versatile structural platform for drug discovery. Furthermore,
the LPTs named lupeol, betulin, and betulinic acid are reported
to possess several biological properties, including anticancer,
anti-inflammatory and antiviral (HIV-1) (Cichewicz and Kouzi,
2004). One of the most well-known member of the lupane family
is betulinic acid [BA, 3β-hydroxy-lup-20(29)-en-28-oic acid], a
LPT found in abundance in many plant species.
In the last 15 years, many BA derivatives bearing a side-chain
modification at C-28 or/and C-3 position have been reported to
inhibit HIV-1 replication (Qian et al., 2009). In fact, bevirimat
(BVM) [3-O-(3′, 3′-dimethylsuccinyl)betulinic acid] is a first-in-
class HIV-1 maturation inhibitor (MI) (Li et al., 2003). However,
BVM failed in phase IIb clinical trials due to naturally occurring
polymorphisms in HIV-1 Gag leading to a natural resistance
of the virus to the drugs (Lu et al., 2011). A number of BVM
analogs with increased hydrosolubility (Coric et al., 2013) or
with an improved antiviral profile (Zhao et al., 2016), in addition
to insights into the structural and functional requirements for
Abbreviations: HIV-1, human immunodeficiency virus type 1; AIDS, acquired
immunodeficiency syndrome; LPTs, Lupane-type pentacyclic triterpenoids; MI,
maturation inhibitors; BA, betulinic acid; BVM, bevirimat; VSV, vesicular
stomatitis virus; SD, standard deviation; SI, specificity index; CC50, cytotoxic
concentration 50%; IC50, inhibitory concentration 50%; RT, reverse transcriptase;
RAL, raltegravir; RLUs, relative luminescence units; PIs, protease inhibitors; NVF,
nelfinavir; ART, antiretroviral therapy; PBMCs, peripheral blood mononuclear
cells; PBLs, peripheral blood lymphocytes.
HIV-1 maturation inhibition (Lin et al., 2016; Tang et al., 2017)
have been reported. Currently, BMS-955176, a second generation
MI with Gag polymorphic coverage, is in phase IIb clinical trials
(Nowicka-Sans et al., 2016).
Despite emerging drug resistance against antiretroviral
therapy, antiretroviral drugs which are currently in development
still target the same steps of the HIV-1 replication cycle than
those antiretroviral drugs which are currently used in the clinic
(Gravatt et al., 2017). Therefore, new drugs targeting different
steps in the viral replication cycle may help to overcome drug
resistance. In previous research from our group, a series of
terpenes of the oleanane and lupane families have demonstrated
potent anti-HIV-1 activity (Osorio et al., 2012; Callies et al.,
2015). Among the lupane triterpenoids, the 28-hydroxy-3-
oxo-lup-20(29)-ene (betulone), 3-oxo-lup-20(29)-en-28-al and
28-acetoxy-3β-hydroxy-lup-20(29)-en-30-al were selected for
future studies (Figure 1). In this work, the mechanism of action
of these three potent anti-HIV-1 lupane triterpenoids has been
investigated for their interaction in different steps of the HIV-1
replication cycle.
Although the structural differences among these compounds
are very subtle, these slight structural variations have the
potential to modulate the affinity for certain targets in the viral
replication cycle or even to target several steps or different targets




The natural compound LPT12 (betulone) was isolated from
the root bark of Maytenus cuzcoina (Celastraceae). Analogues
LPT38 [3-oxo-lup-20(29)-en-28-al] and LPT42 [28-acetoxy-3β-
hydroxy-lup-20(29)-en-30-al] were prepared from betulin and
28-O-acetylbetulin, respectively, as previously described (Callies
et al., 2015).
Cells
The human lymphocyte cell line, MT-2 (Harada et al., 1985) was
cultured in complete RPMI 1640 medium containing 10% (v/v)
fetal bovine serum, 2mM L-glutamine, penicillin (50 IU/mL)
and streptomycin (50µg/mL) (all Whittaker M.A. Bio-Products,
Walkerville, MD). The human kidney derived cell line, 293T,
was obtained from the American type culture collection ATCC
ref: ATCC R© CRL-3216TM and the cervix derived Hela-Tet-On-
Luc, which contains a pTET-ON construct which, in response
to doxycycline, gets active and starts the synthesis of luciferase
gene, was kindly provided by Dr. Eduardo Muñoz of Cordoba
University. Both cell lines were cultured in complete DMEM
medium containing 10% (v/v) fetal bovine serum, 2mM L-
glutamine, penicillin (50 IU/mL), and streptomycin (50µg/mL)
(all Whittaker M.A. Bio-Products, Walkerville, MD). HeLa-Tet-
On-Luc cell line was maintained in complete DMEM medium
in the presence of 100µg/mL of hygromycin and 100µg/mL
of G418 (Both Life Technologies). PBMCs (peripheral blood
mononuclear cells) were isolated from healthy blood donors by
centrifugation through a Ficoll-Hypaque gradient (Pharmacia
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FIGURE 1 | Chemical structures of LPT12, LPT38 and LPT42.
Corporation, North Peapack, NJ) and were resuspended in RPMI
1640 medium supplemented with 10% fetal bovine serum, 2mM
L-gutamine and antibiotics (100 mg/L streptomycin and 100
U/mL penicillin) (all Whittaker M.A. Bio-Products, Walkerville,
MD, USA) before culture at a concentration of 2 × 106 cells/mL.
PBLs were obtained using human CD4 MicroBeads (Biotec)
and activated with Il-2 (300 IU/mL Chiron) for at least 48 h.
Blood samples (Buffy coat) were obtained from the Transfusion
Center of the Community of Madrid (Spain). Proper informed
consent was obtained from each subject in accordance with the
Spanish legislation on blood donor regulations. Confidentiality
and privacy was assured. All cells were cultured at 37◦C in a 5%
CO2 humidified atmosphere and subcultured twice per week.
Viruses and Constructs
The vector pNL4.3-Luc was generated by cloning the luciferase
gene in the HIV-1 proviral clone pNL4.3. Construct pNL4.3-
Ren was generated by cloning the renilla gene in the Luc
site of pNL4.3-Luc (Garcia-Perez et al., 2007) and pJR-Ren
construct was generated by cloning the env gene of HIV-1
JRCSF in the pNL4.3-Ren construct (González et al., 2010).
NL4.3-1-env-VSV-Luc (VSV-Luc) supernatants were obtained
by co-transfection of pNL4.3-Luc-R−E−, a full length HIV-1
DNA that do not express HIV-1 envelope obtained from NIH
(AIDS Research and Reference Reagent Program, NIAID, NIH),
and pcDNA-VSV, DNA for vesicular stomatitis virus (VSV) G
glycoprotein cloned in the pcDNA3.1 construct (Oberlin et al.,
1996). V370A mutation was introduced by PCR in pNL4.3-
Ren clone using the QuickChange Lightning Site-Directed
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) to
produce replication-competent virus (NL-V370A-Ren, mutation
V370A) expressing the renilla reporter gene. pNL4.3-2169-Ren is
extensively described by Garcia-Perez et al. (2007) (PI mutations:
M36I, I54V, L63P, A71V, G73S, L90M).
Recombinant Virus Assay (RVA)
Evaluation of the anti-HIV-1 activity of compounds was
performed in a biosecurity safety level (BSL) 2/3 laboratory in the
Centro Nacional de Microbiología, ISCIII as follows: infectious
supernatants were obtained from 293T cells transfected with the
pNL4.3-Ren construct alone or co-transfection of pNL4.3-Luc-R-
E- and pcDNA3-VSV constructs. All transfections were carried
out with calcium phosphate. Briefly, 293T cells (5·106) were
seeded in culture flask (T75 cm2) 24 h before the transfection.
DNA (40 µg) were then mixed with Cl2Ca (0.75mL) and
HBS buffer (50mM HEPES, 1.5mM Na2HPO4, 140mM
NaCl, pH 7.05) (0.75mL) and added to the culture. After
18 h, culture media is changed for fresh DMEM and 24 h later
supernatants were collected. These supernatants were used to
infect cells in the presence or absence of the compounds to
evaluate anti-HIV-1 activity. Luminescence was quantified 48 h
post-infection. Briefly, cells were lysed with 100 µl of buffer
provided by “Luciferase Assay System Kit with Reporter Lysis
Buffer” or “Renilla Assay System” (both Promega, Madison,
WI, USA). Relative luminescence units (RLUs) were obtained
in a luminometer (Berthold Detection Systems, Pforzheim,
Germany) after the addition of substrate to cell extracts.
Viability was performed in parallel treated cells with the same
concentrations of compound as in the RVA. After 48 h, cell
viability was evaluated with the CellTiter Glo assay system
(Promega, Madison, WI, USA) following the manufacturer’s
specifications. Inhibitory concentrations 50 (IC50) and cytotoxic
concentrations 50% (CC50) were calculated using GraphPad
Prism Software.
Specificity Assay
The Hela-Tet-On-Luc cell line contains two constructs: the
pTET-ON codifies constitutively for rtTA protein that, in
response to doxycycline, gets active and binds to the pTRE2hyg-
Luc starting the synthesis of luciferase gene mRNA leading
to luciferase protein expression. Briefly, cells (105 cells/mL)
were seeded the day before the assay, and then stimulated
with doxycycline (BD Bioscience Clonetech) at 1µg/mL in the
presence or absence of LPTs for 6 h. Then, cells were washed
twice in PBS, lysed and the luciferase activity measured in a
luminometer.
Quantification of Early and Late Reverse
Transcription
MT-2 cells were pre-treated with different concentrations of
LPTs and infected with a NL4.3 wild type HIV-1 for 5 h.
Compound concentrations were chosen on the basis of their
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previously observed EC50 and CC50 values. Total genomic DNA
was isolated with a QIAamp DNA blood mini kit, Qiagen
(Qiagen, Hilden, Germany) and quantified with a Nanodrop-
1000 spectrophotometer (ThermoFisher, Wilmington USA).
Early and late viral DNAs were quantified by qPCR as
previously described (Bermejo et al., 2015). Briefly, 50–100 ng
DNA were mixed with 1µM forward and reverse primers (MA
pr-243 and MA pr-244, and MA pr-275 probe for early RT
and primers MH531 and MH532 and LRT-P probe for late RT)
(Table S1) and 1x GoTaq Probe Universal Master Mix (Promega,
Madison, WI, USA) in a final volume of 16 µL. qPCR was
performed in triplicate in a StepOne Real-Time PCR system (Life
Technologies) using standard cycling conditions. Serial dilutions
of genomic DNA from 8E5 cell line, which contain a single
integrated copy of HIV-1 (Folks et al., 1986), were used as
standard curve. The CCR5 gene was used as endogenous control
(primers CCR5_F and CCR5_R and CCR5 probe in Table S1).
Cell viability was evaluated in mock infected cells treated with
LPTs following the same conditions of the assay.
Quantification of Proviral Integration
Integrated proviral DNA was quantified within whole genomic
DNA from 5 days post-infection. Whole genomic DNA from
HIV-infected MT-2 cells treated with LPTs or controls was
analyzed by nested Alu-LTR PCR, as previously described
(Brussel and Sonigo, 2003; Table S1) using a StepOne Real-Time
PCR System (Life Technologies). In brief, a first conventional
PCR was performed using oligonucleotides against Alu sequence
and theHIV-1 LTR forward primers (Alu 1 andAlu 2, and reverse
primer L-M667 in the Table S1). Then, a second qPCR was
performed using primers Lambda T and AA55M and Taqman
probe MH603 (Table S1) with FAM/ZEN/Iowa Black (Integrated
DNA Technologies) and 1x GoTaq Probe Universal Master Mix
(Promega, Madison, WI, USA). Serial dilutions of genomic DNA
from 8E5 cell line, which contain a single integrated copy of HIV-
1, were used as standard curve. The CCR5 gene was used as
endogenous control (primers CCR5_F and CCR5_R and CCR5
probe in Table S1). Cell viability was evaluated in mock infected
cells treated with LPTs following the same conditions of the assay.
Transfection Assays
MT-2 cells were maintained in culture without stimuli for
1 day prior to the assay. Cells were then suspended in 350
µl of RPMI without serum and antibiotics and added to a
4mm cuvette with 1 µg/106 cells of the construct pNL4.3-
Luc. Afterwards, the mixture was transfected/pulsed at 280V,
1.500µF and maximum resistance using an Easyject plus
Electroporator (Equibio,Middlesex, UK). After transfection, cells
were immediately cultured in RPMI with 10% fetal bovine serum
and antibiotics and treated with LPTs at active concentrations.
Cell cultures were harvested 48 h later and luciferase activity
(RLUs) measured in a luminometer (Berthold Detection Systems,
Pforzheim, Germany).
Maturation Assay
293T cells were seeded in 96microwell plates and the DMEMwas
replacedwith freshmedia 4 h before the experiment. The pNL4.3-
Luc construct was then transfected in each well using the calcium
phosphate method as described above. The DMEM was replaced
18 h later and either LPTs or vehicle (DMSO) were added at
different concentrations; half of the wells were left untreated. The
supernatants were collected 48 h after transfection and the p24
Gag protein was quantified. Then, the supernatants were used to
infectMT-2 cells, controlling for p24 protein amount (10 ng/well)
to avoid any pre-maturation effects on viral particle production.
This assay was performed with selected concentrations of LPTs
and bevirimat was used as a control. LPTs were still present in
viral supernatants used to infect MT-2, but diluted to the final
infectious titre, which was around 10 times in our experiments.
The active fraction of LPT present in the supernatant was
therefore also diluted below IC10 levels. To assure that replication
inhibition was not due to a residual activity, a control of dilution
was used with MT-2 cells infected with untreated supernatants in
the presence of final concentrations of 1/10 diluted LPTs.
Western Blot and Preparation of Extracts
293T cells were transfected with approximately 20 ng of HIV-
1 NL4.3 construct and incubated in the presence of LPTs for
24 h at 37◦C. Supernatants were collected and submitted to
several rounds of concentration by ultra-centrifugation. Total
proteins were extracted from these concentrated supernatants
in 25 µl of lysis buffer (20mM Hepes pH 8.0, 10mM KCl,
0.15mM EGTA, 0.15mM EDTA, 0.5mM Na3VO4, 5mM NaFl,
1mM DTT, leupeptin 1 mg/mL, pepstatin 0.5 mg/mL, aprotinin
0.5 mg/mL, and 1mM PMSF) containing 0.5% NP-40. Protein
concentration was determined by the Bradford assay (Bio-Rad,
Richmond, CA, USA) and 30 µg of proteins were boiled in
loading buffer and electrophoresed in 12.5% SDS/polyacrylamide
gels at 100V for 2 h. Separated proteins were transferred to
nitrocellulose membranes (32mA; 4◦C) for 2 h. Blots were
blocked in TBS solution containing 0.1% Tween-20 and 5%
non-fat dry milk overnight at 4◦C. Immunodetection of specific
proteins was carried out with a monoclonal antibody against
HIV-1 Gag protein (HIV-1 p24 Antibody 1941, Dallas, TX, USA).
Secondary antibodies conjugated with horseradish peroxidase
(HRP) were purchased from GE Healthcare. Proteins were
detected with SuperSignal West Pico/Femto Chemiluminescent
Substrate (Thermofisher, Rockford IL, USA).
Statistical Analysis
All the inhibitory concentrations 50 (IC50) and cytotoxic
concentrations 50% (CC50) were calculated using non-linear
regression, dose-response inhibition curves. ANOVA analysis
was used to determine the value of p (∗p < 0.05, ∗∗p < 0.01
∗∗∗p < 0.001). Both analyses were performed using GraphPad
Prism Software.
RESULTS
Anti-HIV-1 Activity and Viral Entry Inhibition
To evaluate the activity of HIV-1 replication and viral entry,
infections with wild type HIV-1 and VSV-pseudotyped HIV-1
were performed in parallel in the presence of different
concentrations of LPTs or bevirimat (Figure 2). VSV-
pseudotyped HIV-1 is an env gene deleted HIV-1 carrying
the G protein of VSV instead, and thus, it enters target cells
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FIGURE 2 | Dose response inhibition curves of HIV-1 ( HIV) and VSV-pseudotyped HIV-1 ( VSV-HIV) infections of MT-2 cells in the presence of LPT12,
LPT38, LPT42 (0.1–100µM), and bevirimat (0.0001–1µM). Viability was measured in parallel mock infected cell cultures ( Viability). Results are shown as
percentage of RLUs as compared to an untreated control. IC50 values were calculated with GraphPad Prism software, using non-linear regression analysis (Log
inhibitor vs. response). SD, Standard deviation; SI toxicity, Specificity index toxicity (CC50/IC50); SI VSV-HIV, (Specificity index IC50 VSV/IC50 HIV-1).
by a CD4/co-receptor independent pathway. Results are the
mean ± SD of at least 3 independent experiments, each in
triplicate.
The IC50s of the three LPTs (Figure 2) were in the micromolar
range, between 1 and 5µM, while bevirimat IC50 was in the
nanomolar range, as described previously (9 nM). However,
LPTs12 and LPT38 were able to inhibit HIV-1 infection
with no or slight cell toxicity at the concentrations tested
(CC50 greater than 100µM for compound LPT12 and greater
than 20µM for compound LPT38), while compound LPT42
displayed cell toxicity with a CC50 of 14.21µM and an SI of
around 8.
Regarding HIV-1 entry, the three LPTs and bevirimat
inhibited both infections, wild type HIV-1 and VSV-pseudotyped
HIV-1, with similar IC50 values, since specificity index (SI
VSV-HIV) was close to 1 and graphic representations showed
overlapping curves, suggesting an antiviral effect independent of
the HIV-1-envelope. LPT12 displayed the best specificity index
toxicity/activity (higher than 24) while LPT38 and, in particular,
LPT42 showed lower SIs.
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FIGURE 3 | LPTs activity on HIV-1 reverse transcription. Analysis by qPCR of late reverse transcripts in MT-2 cells treated with LPT12 (10, 20, and 40µM), LPT38 (5,
10, and 20µM), and LPT42 (2, 4, and 8µM) and infected with NL4.3 wild type HIV-1 (HIV-1). Results are shown as % of HIV-1 cell copies using 8E5 cells as a
reference of the number of HIV-1 copies in cell culture. The untreated control represents the maximum of HIV-1 copies detected (100%). ANOVA analysis was
performed to determine the value of p (*p < 0.05, **p <0.01,***p < 0.001) and NL4.3 (untreated HIV-1 infection) was used as control.
FIGURE 4 | LPTs activity on HIV-1 integration. Analysis by qPCR of HIV integration in MT-2 cells treated with AZT (1µM), LPT12 (10 and 20µM), LPT38 (5 and 10µM)
or LPT42 (2 and 4µM) and infected with NL4.3 wild type HIV-1 (HIV). Results are shown as % of HIV-1 integrants. The untreated control (HIV) represents the
maximum of HIV-1 integrants detected (100%). CCR5 was used as housekeeping gene. ANOVA analysis was performed to determine the value of p (*p < 0.05,
**p < 0.01,***p < 0.001).
LPTs Effects on Reverse Transcription and
Integration
After cell entry, HIV reverse transcriptase (RT) transcribes viral
RNA to viral DNA, which is transported to the cell nucleus
to integrate in the host cell genome by the viral integrase. We
have measured both the generation of reverse transcripts and
integrated viral DNA in infected cells after the treatment with
LPTs at different concentrations. To do that, we have used
a quantitative PCR assay to quantify HIV-1 LTR sequences
(Figures 3, 4).
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FIGURE 5 | HIV-1 transcriptional activity of selected LPTs. MT-2 cells were transfected with a luciferase construct under the control of the whole HIV-1 genome
(pNL4.3-Luc) in the presence of different concentrations of LPTs or bevirimat. Data are shown as % RLUs as compared to an untreated control (100%).
Concentrations are shown in µM. IC50s were calculated using GraphPad Prism software. SD, Standard deviation.
The amount of late DNA viral transcripts was decreased by
AZT (zidovudine) as compared to a non-treated control (HIV-
1, 100%). LPT12 and LPT42 also diminished the amount of viral
transcripts at the concentrations tested while LPT38 did not.
Raltegravir (RAL) was able to block almost completely
proviral DNA integration (Figure 4). We found a different
pattern of integrase inhibition among LPTs, with LPT12 as
the most powerful integrase inhibitor (complete inhibition at
10µM). LPT38 decreased the amount of integrated copies of
HIV-1 only at 20µM. LPT42 did not show any effect on
integrase activity at the concentrations tested (2 and 4µM)
although a slight tendency could be noted. We increased LPT42
concentration to explore this tendency, but this experiment is
performed at 5 days, treating every 2 days with LPTs, and LPT42
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displayed cell toxicity at the higher concentration used of 8µM
(its CC50 was 14.2µM at 48 h). Interestingly, LPT38 and LPT42
at low concentrations (10 and 2µM) were able to enhance HIV-1
integration.
Therefore, we found that LPT12 was able to inhibit both steps,
reverse transcription and integration, decreasing the amount of
reverse transcripts at 20 and 40µM and total integrated viral
DNA at both concentrations tested (10 and 20µM). LPT38
results showed more variability than any of the other samples,
although it was clear that it decreased the amount of integrated
viral DNA (20µM) and it did not decrease the amount of
DNA reverse transcripts at the concentrations tested. On the
other hand, LPT42 decreased the amount of viral DNA reverse
transcripts but did not decrease viral integrated DNA. To rule
out low DNA detection due to LPTs toxicity, cell viability was
evaluated in mock infected cells treated with LPTs following
the same conditions of the assay and non-toxic concentrations
were used (data not shown). All the experiments are the
mean +/- SD of at least 3 independent experiments, each in
duplicates.
LPTs Effects on Post-integration Targets:
Viral Transcription, Protein Expression and
Maturation
To evaluate the effect on viral transcription, the whole genome of
HIV-1 (NL4.3-Luc) was transfected in MT-2 cells in the presence
or absence of effective concentrations of LPTs. Thus, all the steps
previous to viral transcription are bypassed and it is possible to
evaluate separately the post-integration effect of LPTs. Bevirimat
was used as treatment control (Figure 5).
LPT12 inhibited viral transcription with an IC50 of 11.6µM,
which is almost 3 fold higher than its IC50 for HIV-1 infection
inhibition (3.4µM). LPT42 instead showed an IC50 of 0.4µM,
10 fold lower than its IC50 for HIV-1 infection, and thus, HIV-
1 transcription could be one of its main targets in the viral
replication cycle. LPT38 was able to inhibit HIV-1 transcription
with an IC50 of approximately 20µM, 5 fold higher than its IC50
in infection (4.18µM). Moreover, LPT38 CC50 is greater than
20 and lower than 100µM, and thus, transcriptional inhibition
could be a consequence of cell toxicity, at least in part. As
expected, bevirimat does not alter HIV-1 transcription. After
transcription, viral mRNAs are transported to the cell cytoplasm
and are translated into proteins that will be processed by the
viral protease. Several antiretroviral drugs target the HIV-1
protease (protease inhibitors or PIs) and this could also be a
potential target for LPTs. Thus, the whole genome of HIV-
1 (NL4.3-Luc) was transfected in 293T cells in the presence
or absence of effective concentrations of LPTs, supernatants
were collected and Gag p24 protein measured by ELISA
(Figure 6).
LPTs diminished p24 protein detection as compared to a
non-treated control at all the concentrations tested as well as
the protease inhibitor nelfinavir. Interestingly, bevirimat was
FIGURE 6 | Inhibition of HIV-1 (NL4.3) Gag production in 293T cells by LPT12, LPT38, LPT42, Nelfinavir 0.1µM (NVF), and Bevirimat 0.1µM (BVM). p24 Gag protein
were detected by an ELISA Elecsys system (Roche). Results are shown as percentage of Gag-p24 protein as compared to an untreated control (100%). ANOVA
analysis was performed to determine the value of p (*p < 0.05, **p < 0.01) and NL4.3 (untreated HIV-1 transfection) was used as control.
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also able to lower p24 production, suggesting that inhibition of
maturation decreased p24 production. However, this effect could
be due to the inhibition of HIV-1 transcription and not to a direct
effect on Gag synthesis.
To study the effect of LPTs on the morphogenesis of new
viral particles, 293T cells were transfected with a construct
encoding the whole genome of wild type HIV-1 (NL4.3-Luc) or
bevirimat resistant HIV-1 (NL4.3-V370A-Luc) and treated with
LPTs, nelfinavir or bevirimat. Supernatants from transfected cells
were collected and the amount of p24 Gag protein measured.
Afterwards, these supernatants were used to infect MT-2 cells
with the same amount of Gag protein. Thus, any effect of
LPTs on morphogenesis will produce less infectivity of the
treated supernatant as compared to a non-treated control.
Since compounds cannot be removed from viral supernatants,
infections with dilution controls were performed to rule out a
residual activity of compounds.
All the LPTs inhibited HIV-1 infectivity, although differences
in their potency are easily appreciated (Figure 7). The effect of
both LPT38 and LPT42 on maturation remained around 50%
even at the higher concentrations tested. Moreover, LPT12 was
able to reduce HIV-1 wild type infectivity to 50% at 10µM and
almost completely at 20 and 40µM. However, LPT12’s effect on
bevirimat-resistant HIV-1 (HIV-V370A) seems to be less potent,
since the effect at 20µM remained at 50%, while at 40µM it was
able to inhibit infectivity completely. HIV-1 inhibition by LPTs
diluted to the remaining concentrations in the maturation assay
was not detected (data not shown). Results are the mean +/- SD
of at least 3 independent experiments, each in triplicate.
Protease-Resistant HIV-1 Is Also
Susceptible to LPTs Inhibition
Protease inhibitors (PIs) are a class of antiretroviral drugs used
in ART, although resistances and drug related toxicity have
limited their use. Since LPTs are able to inhibit p24-Gag protein
production, we have investigated their effect on HIV-1 strains
resistant to current PIs.
FIGURE 7 | HIV-1 maturation activity of LPTs and bevirimat. 293T cells were transfected with pNL4.3-Luc or pNL4.3-V370A-luc encoding the whole genome of wild
type HIV-1 or bevirimat resistant HIV-1 in the presence of different concentrations of LPT12, LPT38, and LPT42 and controls nelfinavir (NFV) and bevirimat (BVM).
Supernatants were then collected, p24 Gag protein quantified and used to infect MT-2 cells with the same amount of p24. Results are shown as percentage of RLUs
as compared to a non-treated control (100%). ANOVA analysis was performed to determine the value of p (*p < 0.05,**p < 0.01, ***p < 0.001) and NL4.3 (untreated
HIV-1 supernatants infection) was used as control.
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FIGURE 8 | Effect of LPTs on MT-2 infection with protease inhibitors resistant HIV-1 ( 2169-Ren) as compared to the wild type recombinant virus ( HIV
NL4.3-Ren). Results are shown as percentage of RLUs as compared to an untreated control. IC50 values were calculated with GraphPad Prism software, using
non-linear regression analysis (Log inhibitor vs. response). SD, Standard deviation.
LPTs were able to inhibit saquinavir and lopinavir-resistant
HIV-1 with similar or even lower IC50s than wild type HIV-
1. Only LPT42 showed a slight increase (4.26 fold) in its IC50
when a protease inhibitor resistant HIV-1 was used (Figure 8).
Results are shown as the mean +/- SD of at least 3 independent
experiments, each in triplicate.
Bevirimat-Resistant HIV-1 Is Susceptible to
LPTS Inhibition
As mentioned above, the natural polymorphism in the gag gene
occurring in several HIV-1 strains lead to bevirimat-resistance.
This was the reason why a further pharmaceutical development
of bevirimat as an antiretroviral drug was abandoned. Therefore,
in order to evaluate if LPTs can overcome bevirimat resistance,
we tested the antiviral activity of LPTs and bevirimat as a control
in infections with bevirimat resistant HIV-1 (NL4.3-V370A-
Ren), as compared to wild type recombinant virus (NL4.3-Ren)
(Figure 9). Results are the mean+/- SD of at least 3 independent
experiments, each in triplicate.
The LPTs were able to inhibit both wild type HIV-1 and
bevirimat resistant HIV-1 strains with similar values of IC50,
whereas bevirimat resistance was greater than 450 fold. Thus,
LPTs activity is not altered by the presence of the V370A
mutation, and thus, LPTs can overcome the resistance to
bevirimat due to their multitarget profile.
Inhibition of Processing of HIV-1 Gag
Proteins by LPTs
293T cells were treated with the higher non-toxic concentration
of LPTs, bevirimat or nelfinavir and transfected with a wild
type HIV-1 (NL4.3). Supernatants were then collected for
western blot analysis 2 days after transfection. Accumulation
of CA-SP1 (p25) was analyzed using a monoclonal antibody
against p24 CA antigen. The signature event of anti-maturation
activity is a partial inhibition of CA-SP1 (p25) cleavage that
occurs without interfering with other Gag cleavage sites.
Inhibition of CA-SP1 cleavage should result in an accumulation
of p25.
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FIGURE 9 | Effect of LPTs on MT-2 infection with a bevirimat-resistant HIV-1 BVM resistant HIV) as compared to the wild type virus ( HIV). Results are
shown as percentage of RLUs as compared to an untreated control. IC50 values were calculated with GraphPad Prism software, using non-linear regression analysis
(Log inhibitor vs. response). SD, Standard deviation.
We did not detect differences among the untreated control
and LPT42 and LPT38 treated cells, suggesting a lack
of effect on CA-SP1 processing. As a positive control of
Gag processing, a protease inhibition event was detected
in samples treated with nelfinavir at the concentration of
1µM. However, samples treated with LPT12 did not show
an accumulation of p25 as expected. It did not show the
same inhibition pattern as nelfinavir since it did not increase
the amount of p55. Instead, treatment with LPT12 showed
a decrease in p24 processing in comparison to the non-
treated-wild type virus positive control where both p25 and
p24 are detected at higher concentrations (Figure 10). Results
are shown as a representative one of three independent
experiments.
LPTs Inhibits HIV-1 Infection in PBLs
Finally, we have tested the antiviral effect of LPTs in PBLs
to corroborate their activity in the natural target of HIV-1, T
cells. PBLs were isolated from healthy donors and pre-activated
with IL-2 for at least 48 h before the experiment to allow HIV-
1 infection. LPTs inhibited HIV-1 infection in PBLs, although
some differences with MT-2 infections were found. While LPT12
and bevirimat displayed IC50 values similar to those shown in
MT-2 infections, LPT38 and LPT42 increased their IC50 values
approximately by a factor of 4. Toxicity values were higher in
PBLs than in MT-2 for all the three LPTs, although LPT12
showed a CC50 higher than its IC50 (Figure 11). Results are the
mean +/- SD of at least 3 independent experiments, each in
triplicate.
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FIGURE 10 | Detection of p24 processing in wild type NL4.3 HIV-1 strain after
treatment with LPTs. 293T cells were transfected with HIV-1 (NL4.3) and
incubated in presence of LPT12 40µM, LPT38 20µM, LPT42 8µM, bevirimat
(BVM) 0.1µM, nelfinavir (NFV) 0.1µM or left untreated for 24 h at 37◦C. Two
days after transfection supernatants were collected and submitted to several
rounds of concentration by ultra-centrifugation. Total proteins were then
extracted and immunodetection of specific proteins was carried out with a
monoclonal antibody against HIV-1 Gag p24 antigen.
DISCUSSION
Since the approval of raltegravir in 2007, antiretroviral therapy
is mainly focused in the development of new formulations or
combinations of currently approved drugs. However, HIV-1
infection is not cured by current therapy, but viral concentration
is decreased to undetectable levels without eradicating the virus.
Thus, new approaches are needed for the treatment of HIV-1
infections. Bevirimat was developed by chemical modification
of betulinic acid, a lupane-type triterpene, as a new anti-HIV-1
candidate inhibitor of HIV-1 maturation (Sakalian et al., 2006).
Maturation was, and still is, a drug target in HIV-1 lifecycle not
reached by current ART and thus, maturation inhibitors have
gained a considerable interest as potential new antiretrovirals.
However, in clinical trials, bevirimat showed less activity than
expected because of the presence of a natural mutation in
Gag protein that conferred resistance to some strains of HIV-
1 (Lu et al., 2011). Therefore, new derivatives of betulinic acid
have been isolated or synthetized to overcome this resistance
(Qian et al., 2009). In contrast to our investigations, these new
derivatives have been tested only as maturation inhibitors. In
this work, three powerful anti-HIV-1 inhibitors were selected
from a set of previously screened lupane-triterpenoids (Callies
et al., 2015) to study their potential as maturation inhibitors, as
well as their activity on other targets in the HIV-1 replication
cycle.
The chemical structure of the three LPTs is very similar, with
slight variations in their substituents. Previous reports showed
that betulinic acid derivatives with side chain modifications at
the C28 position inhibited viral entry (Holz-Smith et al., 2001)
targeting the V3 region of HIV-1 gp120 (Huang et al., 2006).
Thus, betulinic acid displays other anti-HIV-1 activities besides
maturation inhibition, and consequently, we have explored viral
entry as a potential target of LPTs. LPTs inhibited infections with
wild type HIV-1 and VSV-pseudotyped HIV-1 which enters T
cells independently of CD4 and co-receptors, with similar IC50
values suggesting a non-entry target for all the LPTs and, of
course, for bevirimat (Figure 2). Infection inhibition was also
evident in primary human T cells (PBLs), ruling out a potential
target in MT-2 cell line not related to regular T cells (Figure 11).
Furthermore, bevirimat was not able to inhibit HIV-1
infection completely, as shown in the graphs (Figure 2) for both
MT-2 cells and PBLs at the concentrations tested. This can be
explained because it targets a post-transcriptional step, viral
maturation, and our recombinant virus (RV) system allows us
to measure HIV-1 transcriptional activity (in RLUs). We have
consistently found this post-transcriptional effect for protease
inhibitors (Callies et al., 2015), as well as for saquinavir and
lopinavir (Figure 8). Therefore, the first round of replication
is detected if a post-transcriptional target is inhibited and
RLUs would be obtained. However, the following rounds of
replication will be inhibited and a decrease in RLUs would
be detected, although RLUs from the first round will still be
present. This peculiarity of our recombinant virus system leads
us to recognize drugs with pre- and post-transcriptional targets
by performing a simple infection experiment. Interestingly,
LPTs inhibited HIV-1 replication completely and thus
they likely have a pre-transcriptional target not related to
maturation.
Several antiretrovirals act through inhibition of reverse
transcription (RT), but little is known about the effect which
triterpenes exhibit in this crucial step of the viral replication
cycle. Rukachaisirikul et al. showed that protostane triterpenes
inhibited RT activity in an enzymatic assay, although these
compounds were cytotoxic in cell culture (Rukachaisirikul et al.,
2003). Another study reported a potent anti-HIV-1 activity
through anti- reverse transcriptase activity of secodammranane
triterpenoids in a times of addition experiment. Moreover,
this study showed that these triterpenes were able to inhibit
other viruses such as simian immunodeficiency virus and
murine leukemic virus (Esimone et al., 2010). Herein, we
demonstrate that lupane-type triterpenoids could inhibit RT
activity since LPT12 and LPT42 diminish the amount of
viral DNA reverse transcripts produced in infected cells
to the same extent than the reverse transcriptase inhibitor
AZT. Interestingly, LPT38 treatment did not decrease total
viral DNA amount so this might indicate the presence of
an additional, unknown pre-transcriptional target. LPT12 did
not inhibit reverse transcription at 10µM, but it did at
20µM, so it might also have another target in the HIV-
1 replication cycle, since its infection IC50 is around 3µM.
On the other hand, LPT42 decreased viral DNA amount
at a concentration of 2µM, similar to its infection IC50
(1.6µM).
Hence, two bevirimat-related compounds, LPT12 and
LPT42, acted on a pre-transcriptional stage, inhibiting reverse
transcription. This could explain the observation that these
compounds were able to inhibit HIV-1 infection completely
(Figure 2), while bevirimat did not with the concentrations
tested. In contrast, LPT38 did not inhibit reverse transcription.
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FIGURE 11 | Dose response inhibition curves of HIV-1 ( HIV) replication in primary human lymphocytes (PBLs) by LPT12, LPT38, LPT42, and bevirimat. Viability
was measured in mock infected cultures ( Viability). Results are shown as percentage of RLUs as compared to an untreated control. IC50 values were calculated
with GraphPad Prism software, using non-linear regression analysis (Log inhibitor vs. response). SD, Standard deviation; SI toxicity, Specificity index toxicity
(CC50/IC50).
There is no previous literature about the activity of lupane
terpenes in HIV-1 integration. We found that two LPTs,
LPT12, and LPT38, inhibited integration while LPT42 did
not. The slight differences in their structure are crucial for the
integrase inhibition. LPT38 decreased the number of integrated
copies of HIV-1 as expected, since its antiviral activity is only
observed at 20µM and is thus likely to have another pre- or
post-transcriptional viral target to reach its full activity.
LPTs are involved in HIV-1 transcription, as we have
previously shown with oleanane triterpenes (Osorio et al., 2012).
Again, slight structural differences of the LPTs lead to differences
in their activity. In transcription, LPT42 is as powerful as in
HIV-1 inhibition while LPT12 and LPT38 were not, suggesting
that chemical features in LPT42 such as the hydroxyl or the
acetate groups at the C-3 and C-28 positions, respectively, which
could be able to act as H-bond acceptor/donor in the interaction
with a receptor, are important trends for this activity (Figure 1).
We described previously for oleanane terpenes that the overall
oxidation level of the molecule, the regiosubstitution patterns,
and the type of functional group, contributed to the inhibition
of HIV-1 transcription (Osorio et al., 2012). This could be true
also for LPTs, since LPT42 oxidation level in C-3 is different from
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TABLE 1 | Summary of the IC50 values (µM) and active concentrations obtained for LPT12, LPT38, LPT42, and Bevirimat in the different targets of the HIV-1 replication
cycle studied.
µM LPT12 LPT38 LPT42 BVM
HIV infection MT-2 3.40 ± 1.76 4.08 ± 0.18 1.66 ± 0.17 0.009 ± 0.005
PBLs 2.31 ± 1.62 15.90 ± 1.58 7.26 ± 0.73 0.008 ± 0.003
PIs resistant HIV-1 2.70 ± 1.84 2.43 ± 2.86 7.07 ± 2.29 ND
BVM resistant HIV-1 2.64 ± 0.03 5.30 ± 1.84 2.15 ± 0.37 4.18 ± 0.03
Reverse transcription* 20 >20 4 ND
Integration* <10 ≈20 >4 ND
HIV-1 transcription 11.6 ± 2.9 ≫20 1.9 ± 0.9 >50
Gag-p24* 10 20 2 0.1
HIV-1 maturation HIV-1* 10 20 2–8 ≈0.1
BVM resistant* 20 20 2–8 ND
*Approximate values.
LPT12 and LPT38, explaining in part its higher activity in HIV-1
transcription.
It has been previously described that coevolution of gag
mutations with protease mutations could occur and patients who
fails protease inhibitors (PIs) therapy could fail to respond to
bevirimat therapy (Fun et al., 2011) probably because maturation
involves the interaction with Gag HIV-1 protein in the protease
cleavage site. Our findings show that all of them, including
bevirimat, inhibited the amount of p24 Gag production. This fact
is expected for two reasons: the inhibition of p24 production,
with the subsequent accumulation of its precursor p25, is
the described mode of action of maturation inhibitors and,
secondly, transcriptional inhibition could diminish the amount
of p24 production. The effect on protease activity was further
studied by evaluation of LPTs activity in infections performed
with HIV-1 resistant to PIs. We found that mutations that
confer resistance to PIs did not modify the IC50 of LPTs and
therefore, LPTs will be effective also in the infection with
PIs resistant virus, at least with the mutations described for
the viral strains used (M36I, I54V, L63P, A71V, G73S, and
L90M).
We have used 3 different approaches to study LPTs activity
as maturation inhibitors, the main target of bevirimat and
some related lupane triterpenoids in HIV-1 cycle: evaluation
of LPTs effect on viral particles production-maturation, LPTs
activity in bevirimat resistant HIV-1 and LPTs activity on CA-SP1
processing (p25-p24). Maturation is a target not easy to study in
a cellular environment, particularly if the compounds to analyze
have more than one target in the replication cycle, since results
can be interfered by their activity on previous targets. However,
our results suggests low efficacy as maturation inhibitors for both
LPT38 and LPT42. On the other hand, LPT12 clearly inhibited
wild type HIV-1 maturation although, when a bevirimat resistant
virus was used, LPT12 showed a slight susceptibility to the
resistant virus, although no differences in IC50s were found in
infections performed with wild type and bevirimat resistant HIV-
1. This data indicate that the other targets in HIV-1 replication
cycle, reverse transcription, integration and viral transcription,
bypass the resistance to bevirimat. This fact was confirmed
when CA-SP1 processing (p25-p24, Figure 10) was evaluated,
since LPT38 and LPT42 did not show any effect in the p25/p24
ratio, confirming their low activity as maturation inhibitors and
LPT12 activity was not clear in all the experiments performed.
However, the three LPTs did not accumulate p55, which is a
difference with the activity of protease inhibitors (nelfinavir) and,
thus, LPTs target will not work in the same way as protease
inhibitors.
In summary, three lupane triterpenoids structurally related to
the well-known betulinic acid bevirimat were found to inhibit
HIV-1 infection through more than one target. Thus, they
act as promiscuous compounds by acting on multiple steps
in the HIV-1 replication cycle in both MT-2 cells and PBLs.
LPT12 inhibits HIV-1 infection, targeting reverse transcription,
integration, viral transcription, Gag production and maturation.
LPT38 also inhibits HIV-1 infection by targeting integration, viral
transcription and Gag production. Finally, LPT42 targets reverse
transcription, viral transcription and Gag production (Table 1).
The multi-target profile of these compounds is a new feature
of lupane terpenes that could be useful to overcome HIV-1
resistance by modulating multiple targets simultaneously. This
approach, which plays an increasing role in pharmaceutical R&D,
could facilitate the discovery of the next generation of anti-HIV-1
agents.
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